

male samples characterizes the response to fetal fraction and relates directly to the ability of the system to detect aneuploidy. As shown in Figure 2, the value of ratio X was similar when measured on HiSeq and Next 500 Systems. This result indicates similar amplitude of copy number variation in response to fetal fraction.

In addition to characterizing response to fetal fraction in male samples, signal variation for unaffected samples on target chromosomes (13/18/21) was characterized by percent coefficient of variation (%CV) of chromosomal ratios. Even though %CV is measured on unaffected samples, it determines analytical sensitivity for detecting aneuploidies. The %CV for chromosomes 13, 18, and 21 was consistent between platforms (Table 2), suggesting nearly identical assay performance regarding detection of fetal aneuploidy for these chromosomes across the HiSeq and NextSeq 500 Systems.




Figure 2: High Concordance of Ratio X Values—The high level of concordance achieved when plotting the ratio X of each sample generated on the NextSeq 500 and HiSeq Systems demonstrates that both produce the chromosomal ratios required for detection of fetal aneuploidy. Grey: male fetus. Green: female fetus.

Table 2: Low, Consistent %CV Values Achieved With the HiSeq and NextSeq 500 Systems

	% CV HiSeq 2500 System	% CV NextSeq 500 System
Chr. 13	0.197%	0.202%
Chr. 18	0.217%	0.200%
Chr. 21	0.294%	0.274%

Experiment 2—Design

A second sample set of 112 samples was sequenced on both the HiSeq and NextSeq 500 Systems. The second sample set contained 9 samples that tested positive for fetal trisomy 21 by the verifi Prenatal Test. Samples were prepared and sequenced according to the protocols outlined in the “Experiment 1—Design” section.

illumina • 1.800.809.4566 toll-free (U.S.) • +1.858.202.4566 tel • techsupport@illumina.com • www.illumina.com

For Research Use Only. Not for use in diagnostic procedures. Not available in all countries or regions.

© 2015 Illumina, Inc. All rights reserved. Illumina, HiSeq, NextSeq, TruSeq, verifi, and the pumpkin orange color are trademarks of Illumina, Inc. and/or its affiliate(s) in the U.S. and/or other countries. Pub. No. 1570-2014-053 Current as of 23 March 2015

Experiment 2—Analysis and Results

Data obtained for the second set of 112 samples was used to generate normalized chromosome 21 values (NCV 21, or the z-scores used for NIPT classification). As shown in Figure 3 and predicted by previous %CV analysis, the sequencing instrument used did not affect z-scores or the ability to detect aneuploidy in paired samples.




Figure 3: Nearly Identical NCV 21 Values—Plotting NCV 21 values of 112 samples sequenced using both the HiSeq and NextSeq 500 Systems shows nearly identical values, indicating the ability of both systems to determine the presence of fetal trisomy 21 in NIPT. Grey: unaffected. Green: affected T21.

Summary

This study assessed data relating to key NIPT metrics for 663 matched samples processed on both the HiSeq and NextSeq 500 Systems. Results indicate that the NextSeq 500 System generates ratio X, %CV, and NCV 21 data that is comparable to the HiSeq System.

Learn More

To learn more about Illumina solutions for NIPT, visit www.illumina.com/nextseqnote.

Reference

1. Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. *Obstet Gynecol.* 2012;119(5):890-901. doi:10.1097/AOG.0b013e31824fb482.
2. Futch T, Spinosa J, Bhatt S, de Feo E, Rava RP, Sehnert AJ. Initial clinical laboratory experience in noninvasive prenatal testing for fetal aneuploidy from maternal plasma DNA samples. *Prenat Diagn.* 2013;33(6):569-574. doi:10.1002/pd.4123
3. Bianchi DW, Rava RP, Sehnert AJ. DNA sequencing versus standard prenatal aneuploidy screening. *N Engl J Med.* 2014; 7;371(6):578. doi: 10.1056/NEJMc1405486.

